Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Paralympic gold medalist Oscar Pistorius is to remain behind bars after a decision to release him on parole was delayed again.
The family of the bus driver who was involved in Saturday's crash has said he is "devastated to the core" about what has happened.
A headteacher has payed tribute to a seven-year-old boy who was killed in a bus crash in Coventry at the weekend.